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Abstract 
 
‘These skin patch patients seem happier’. 
 
This chance remark from the pain clinic nurse, in 2007, was the seed that grew 
into this study. Increasingly, patients prescribed transdermal opioids, were 
being referred to the clinic. These medicines became available in North West 
Tasmania during the previous year. Until then, oral opioids were the mainstay of 
intractable chronic non-cancer pain (CNCP) treatment. 
 
The north west of Tasmania is a predominantly rural area of 22,492 square 
kilometres, with a population, in 2008, of 111,100 people. Access to healthcare 
is often more difficult here, than in with the major population centres, due to the 
‘tyranny of distance’ and reduced specialist medical and allied health services 
available locally 
 
This pain clinic, based at the NW Regional Hospital, opened its doors in 2005. 
The previous ad hoc system, provided by the anaesthetic department acute 
pain service, had become overwhelmed by the persistent pain workload. The 
catalyst for this was the well publicised withdrawal of VioxxTM (rofecoxib) in 
2004, highlighting the potential long term cardiovascular adverse effects of both 
cyclo-oxygenase-2 selective inhibitors (coxibs) and standard non steroidal anti-
inflammatory drugs (NSAIDs). Quickly, opioid analgesics were replacing coxibs 
xvi 
 
and NSAIDs for the management of the painful musculoskeletal degenerative 
changes associated with aging, as their long term safety profile was predictable.  
 
Long-term opioid management is complex, in achieving a balance between 
efficacy of pain relief and minimisation of harm. Efficacy of pain relief requires 
stable therapeutic levels of medication, which may be difficult to achieve even 
with long acting oral opioid preparations. Minimisation of harm requires the 
reduction of untoward patient effects and the prevention of opioid diversion to 
the community. This requires significant healthcare resources to optimise 
patient care. Our newly arriving patients who were being treated with 
transdermal opioids seemed to be following a simpler path. 
 
If patients seemed happier with these transdermal medicines, they might need 
less frequent healthcare access. This concept framed the study. There was no 
published data available on the effect of the route of opioid analgesia, on 
healthcare utilisation, by persistent pain patients. This was the first Australian 
study to measure this in a rural context. 
 
This prospective longitudinal study compared 1804 months of healthcare 
activity by 198 subjects using oral or transdermal opioids. Subjects recorded 
details of all their ‘out of home’ healthcare contacts, together with the type, 
route, and dosage, of their opioid medication(s). 
 
xvii 
 
There is a personal socioeconomic cost involved in accessing healthcare, and 
this increases in rural areas. Pain patients may use additional analgesics with 
their opioid analgesics. These related issues were assessed, as any benefit 
from reduced healthcare activity would likely be lost if patient costs, or their 
need for additional analgesics, increased.  
 
The study revealed that General Practitioner contacts were reduced 
significantly, by one fifth, and there was a trend towards less total healthcare 
activity, by patients using transdermal opioids. Pharmacy visits remained 
unaffected, probably as a consequence of the regularly repeated dispensing of 
all subject medications. 
 
Their personal socioeconomic costs involved remained unchanged. This 
included all out of pocket healthcare and travel expenses, together with the time 
taken to access this healthcare. On average, the subjects spent five hours each 
month and had out of pocket expenses of over one hundred dollars to do this. 
 
Additional analgesic and sedative use was unchanged, but there was a trend 
towards reduced use of short acting opioid analgesics for ‘breakthrough’ pain. 
Whether some patients have individual characteristics that enhance their 
response to the ‘steady state’ delivery of opioid medication by the transdermal 
route is currently unknown. 
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If the risk of diversion is a consideration in prescribing opioid analgesics for rural 
pain patients then, at present, transdermal opioids are the safer option. If this 
leads to a reduction in the prevalence of opioid diversion in NW Tasmania, 
there are considerable economic benefits, both from a reduction in self-harm, 
and from drug enforcement costs. 
 
In NW Tasmania, transdermal opioids do seem to offer a benefit to patients 
compared to oral opioids. Reducing the frequency of General Practitioner visits 
is a good outcome in this rural area of limited health resources. Transdermal 
opioids are relatively simple and safe to use, both for prescribers and patients. 
As the population here ages, there will be an increased requirement for safe 
and effective pain relief for both degenerative and malignant pain. With the 
further development of these preparations, transdermal matrix opioids may 
open the door to the further relief of suffering and the living of fulfilled lives. 
 
This study has filled a gap in the knowledge of the effective management of 
opioid treated CNCP patients in rural Tasmania. This may be applicable to 
similar rural areas in Australia and elsewhere, where healthcare resources are 
limited. 
 
 
This thesis is presented as a series of published and submitted papers.  Some 
repetition of text is unavoidable.
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1 Persistent pain, opioids, and healthcare use in  NW 
 Tasmania 
 
1.1 Introduction 
 
‘Do transdermal (skin patch) opioids reduce healthcare use in a rural pain 
population?’ 
 
This question was asked at a presentation of the newly available transdermal 
preparation of buprenorphine (NorspanTM), during the 2006 Scientific Meeting of 
the Australian Pain Society. Physicians knew then that this route of delivery was 
as effective as the oral route in providing sustained analgesia (1). As this 
question would affect my work as a pain medicine physician in NW Tasmania, 
this question was worth addressing. 
 
Persistent (non cancer) pain is increasing as the population ages, due mainly to 
the increase in spinal degeneration from osteoarthritis and osteoporosis (2). 
The more severe pains often respond to opioid medicines, and these may be 
the safest option (3). Patients with opioid responsive persistent pain utilise a 
variety of healthcare resources including general practitioner (GP), pain 
medicine, and pharmacy services. In rural areas, such as NW Tasmania, 
access to these services often involves significant travel, time, and financial 
burdens.  
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Traditionally, patients with opioid responsive persistent pain have been treated 
with oral opioid medicines of immediate and/or slow release effect (4).  Many 
patients, particularly the elderly, have difficulty with opioid medicines and may 
require ongoing health-care support (5). In rural areas, this may be a significant 
burden for themselves and their families. 
 
In 2005/6, two developments occurred in the availability of transdermal opioid 
medicines in Australia: 
 
1 Buprenorphine transdermal matrix was introduced to the Australian 
market by Μundipharma P/L in three low dosages (5 μg/hr, 10 μg/hr, and 20 
μg/hr), and became available through the Pharmaceutical Benefits Scheme 
(PBS) (1,6). 
 
2 Fentanyl transdermal matrix was introduced to the Australian market by 
Janssen-Cilag P/L (replacing the previous reservoir preparations), and became 
available through the PBS (7). This range was expanded by the introduction of 
a lower dosage12 μg/hr preparation (8). 
 
Since then, the possibility of treating opioid naïve subjects safely with low dose 
transdermal opioid preparations has become a reality. Opioid medications are 
often difficult to manage, both for the patient and for the prescriber (9,10). The 
patient must keep to a regular dosing schedule, yet may experience unwanted 
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opioid effects. The prescriber must provide a safe and reliable means of 
providing the opioid medicine, whilst fulfilling all regulatory requirements (11). 
These factors, together with the underlying pain condition all have a part to play 
in healthcare use by this group of rural patients. If it is possible to reduce this 
burden by changing the route of opioid delivery, both patient and prescriber may 
benefit. This is the rationale for the present study. 
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1.2 Persistent pain 
 
Persistent (chronic) pain is pain that persists longer than the temporal course of 
natural healing, associated with a particular type of injury or disease process 
(12). An understanding of persistent pain now includes the impact that the mind 
has in processing and interpreting pain signals.  
 
The International Association for the Study of Pain (IASP) defines pain as ‘an 
unpleasant sensory and emotional experience associated with actual or 
potential tissue damage, or described in terms of such damage’ (13). Pain is 
subjective in nature and defined by the person experiencing it. The term 
‘chronic non-cancer pain’ (CNCP) is often used to describe all non-malignant 
persistent pain 
 
From earliest times, pain was considered an injury/response phenomenon, 
which in classical times was documented as a ‘hard-wired’ mechanism (Figure 
1.1). 
 
5 
 
 
Figure 1.1 Decartes’ concept of the pain pathway (14). 
 
In 1647, Rene Descartes wrote of the pain pathway: ‘just as by pulling at one 
end of a rope one makes to strike at the same instant a bell, which hangs at the 
other end’. The advances in gross nervous system anatomy reinforced this 
concept in the eighteenth and nineteenth centuries. 
 
In the twentieth century (following both the First and Second World Wars), 
increasing attention was focused on the treatment of persistent pain in injured 
war veterans. In 1961 the first multidisciplinary pain unit was established at the 
University of Washington School of Medicine, Seattle, led by John Bonica, an 
anaesthetist, who was instrumental in establishing the IASP. Increased 
multidisciplinary research into pain mechanisms soon bore fruit. 
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In 1965, Ronald Melzack, a Canadian psychologist, and Patrick Wall, a British 
physiologist, proposed the gate control theory of pain. Their theory asserts that 
activation of nerves that do not transmit pain signals (L) can interfere with 
signals from pain fibres (S) and inhibit an individual's perception of pain. This 
breaks away from the ‘hard-wired concept’ and opens up the myriad ways in 
which the experience of pain may be modulated (Figure 1.2). 
 
 
Figure 1.2 The gate control theory of pain (15). 
 
To the gate control theory was added the conceptualising of persistent pain 
(onion skin) model advanced by John Loeser, a neurosurgeon. The noxious 
stimulus (nociception) leads to pain, which leads to suffering, which leads to 
pain behaviour (which may be observed). This concept provided a framework 
for the many aspects of persistent pain that are classed as pain behaviour 
(Figure 1.3). 
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Figure 1.3 The conceptualisation of persistent pain (16). 
 
It is this pain behaviour, in all its manifestations, that is the driver of health care 
use in persistent pain populations. Analgesic use (including opioid use) is but 
one aspect of the whole. 
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1.3 Opioid analgesics (opioids) 
 
‘Among the remedies, which it has pleased Almighty God to give to man to 
relieve his sufferings, none is so universal and so efficacious as opium’ 
 
- Thomas Sydenham, 1624-1689 
(English physician, and officer in the Parliamentary Army during the Civil War). 
  
‘The angelic face of opium is dazzlingly seductive, but if you look upon the other 
side of it, so much it will appear altogether a Devil. There is so such poison in 
this all-healing medicine that we ought not to be by any means secure or 
confident in the frequent and familiar use of it.’ 
 
- Thomas Willis, 1621-1673,  
(English physician, and founding member of the Royal Society). 
 
Opioids as opium, have been used for pain relief and for recreation for 
thousands of years. Originating from central Asia, their use spread along the 
great trade routes to China, South East Asia, India, the Middle East, Africa, and 
Europe. Thomas Sydenham praised God for the analgesic effect, but Thomas 
Willis warned of the dangers of recreational use. 
 
Opioids in clinical use are primarily μ receptor agonists, active mainly in the 
central nervous system, but also on other tissues. Morphine, oxycodone, and 
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methadone, are commonly used as oral preparations, whilst buprenorphine and 
fentanyl are available as transdermal reparations. 
 
The provision of pain relief was fundamental to the palliative care movement 
(17). In 1967, Cicely Saunders of the St Christopher’s Hospice in London 
focused on rationalising the regular use of opioids in the care of the dying (18). 
Round the clock dosing of short acting opioids provided stable prolonged 
analgesia. This encouraged the development of longer acting opioid 
preparations (19). 
 
The development of modified release oral opioids reached fruition in 1985 when 
the original MS ContinTM morphine preparation was marketed. The sustained 
release mechanism is a wax inside the tablet (not the coating on the outside) 
that when ingested, encases the released morphine sulphate. 
 
Μultidisciplinary pain clinics have since rationalised the use of opioid 
medications for the treatment of non-cancer pain (20). This began with Robert 
Portenoy in 1986 at the Sloan Kettering Cancer Center in New York (21). Many 
modified release opioids have since been developed, using both morphine and 
oxycodone. 
 
In parallel with the development of modified release oral opioid preparations, 
the transdermal route has been pursued. These have transformed from the 
10 
 
original liquid reservoir fentanyl, to the modern matrix preparations of both 
fentanyl and buprenorphine. 
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1.3.1 Modified release and long acting orally administered opioid 
analgesics (oral opioids) 
Modified release oral opioids are manufactured by combining a polymer, 
whether natural or synthetic, with the opioid in such a way that the opioid is 
released from the material in a pre-designed manner (22). This is usually 
adjusted to enable twice daily (12-hour) dosing regimens, which seem most 
convenient. These preparations are more commonly known as oral controlled 
release (OCR) opioids. 
 
Some opioids have naturally prolonged duration of action due to prolonged half-
lives (23). Buprenorphine and methadone are both examples, but only 
methadone is available via the PBS for persistent pain (oral buprenorphine is 
available for maintenance therapy for opioid dependency). 
 
Morphine is an agonist at all opioid receptors, particularly the μ receptor. It is 
the prototypical opioid, and can be given via many routes of administration (24). 
After oral use, morphine is well absorbed; however, significant first-pass 
metabolism reduces the bioavailability to approximately 30% of the original 
dose. Oral administration results in a greater production of metabolites than 
parenteral administration. The metabolites comprise mainly morphine-3-
glucuronide (M3G) and morphine-6-glucuronide (M6G). They are both excreted 
by the kidneys and accumulate in patients with renal impairment. M6G is a 
potent analgesic and contributes to the analgesic effect when morphine is given 
long term. M3G has no analgesic activity itself and may antagonise the 
12 
 
analgesic activity of morphine and be responsible for neurotoxic symptoms. The 
elimination half-life of oral morphine is 1.5 to 2 hours, and the duration of 
analgesic effect is 3 to 6 hours (25). 
 
The oral route is preferred for long-term administration. In Australia, there are 
three modified release preparations of oral morphine available, MS Contin, MS 
MonoTM, and KapanolTM (26-28). MS Contin is formulated in an enteric-coated 
matrix tablet form (B) whereas MS Mono and Kapanol are formulated in a micro 
bead matrix capsule form (A) (Figure 1.4). 
 
 
Figure 1.4 Representation of (A) an extended release bead formulation, and 
(B) a sustained release matrix tablet (22). 
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Oxycodone is up to two times as potent as morphine orally, because of its 
higher bioavailability (up to 90%). It is metabolised by CYP2D6 to 
oxymorphone, whose role in providing analgesia after a dose of oxycodone is 
thought to be limited (29). Efficacy of oxycodone is similar to that of morphine. 
OxycontinTM is a modified release preparation with a biphasic action. One third 
of the oxycodone is in the enteric coating and is immediately available. The 
remainder is within the matrix and is gradually released (30). 
 
Methadone is a μ agonist with several features that differentiate it from most 
opioids. It has N-methyl-D-aspartate (NMDA) receptor antagonist activity (31). 
Persistent tissue damage generating neuropathic (nerve) pain can activate 
these receptors in the spinal cord, leading to hyperalgesia (central 
sensitisation). Its elimination half-life is biphasic and variable. This can cause 
problems with accumulation and toxicity (32).  
 
Methadone has no active metabolites, an oral bioavailability of around 80%, 
high lipid solubility, and is relatively inexpensive. It is well absorbed orally and 
does not undergo extensive first-pass metabolism. There is marked individual 
variability in the half-life of methadone, between 15 to 60 hours has been 
reported. Methadone can be used twice daily for maintenance management of 
chronic pain (33). 
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1.3.2 Transdermally administered opioid analgesics (transdermal 
opioids) 
Transdermal opioid matrix systems consist of a backing layer, an adhesive 
matrix layer with the opioid, and a removal foil on skin placement (Figure 1.5). 
 
 
Figure 1.5 Cross-section through a matrix patch 
 
When the skin is used as a port for drug delivery into the systemic circulation, 
there are several advantages compared to oral, sublingual, or parenteral 
administration. Since the gastrointestinal tract is by-passed, poor absorption or 
high hepatic first-pass metabolism can be avoided. The rate of drug delivery 
can be controlled and stable plasma levels achieved. This may improve long 
term analgesia and reduce adverse effects (34). 
 
Buprenorphine is a partial agonist at μ opioid receptors and an antagonist at κ 
opioid receptors, with a prolonged duration of action (35). It is available as 
sublingual, parenteral and transdermal preparations. Buprenorphine is subject 
to considerable first-pass metabolism following oral administration.  
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Buprenorphine has high receptor affinity and slow dissociation from the 
receptor, with the analgesic effect persisting longer than the elimination half-life. 
The 7-day transdermal patch (NorspanTM) reaches steady state after 3 days, 
and plasma levels decrease by 50% approximately 12 hours after the patch is 
removed (36) (Figure 1.6). 
 
 
Figure 1.6 Comparison of plasma concentrations of buprenorphine after 
single application of 35 µg/hr patch (removed after 72 h) and sublingual dosing 
of 400 µg buprenorphine, eight hourly (37). 
 
Fentanyl is a very potent synthetic opioid, with a short duration of action (38). It 
is used in both acute and chronic pain management. It can be administered via 
the oral mucosa (lozenge), parenterally (IM, IV, SC, intrathecal, epidural), 
transdermally (patch) and intranasally. 
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Fentanyl is metabolised in the liver to inactive products and is suitable for 
patients with renal failure. The three-day transdermal preparation (DurogesicTM) 
reaches steady state after 24 hours and plasma levels decrease by 50% 
approximately 12 hours after the patch is removed (Figure 1.7). 
 
Figure 1.7: Mean serum concentration of fentanyl as a function of time after 
repeat 72-hour application of Durogesic 25 µg/hr (n=10) (39). 
17 
 
1.4 Healthcare use 
 
People use healthcare when they perceive they have a health problem that 
needs fixing or managing. People with persistent pain are rarely ‘fixed’ and 
need significant managing of their pain morbidity and associated problems. 
Fixable persistent pain is usually large joint degeneration, treatable by 
replacement arthroplasty (40). 
 
The vast majority of persistent pain is driven by degenerative musculoskeletal 
change of age or injury. The National Health Survey collects information on all 
long-term conditions particularly focusing on chronic diseases such as arthritis 
and osteoporosis, asthma, cancer, diabetes, heart and circulatory conditions, 
mental health and obesity.  
 
In the 2007-08 survey, 15% of persons reported that they currently had arthritis; 
13% of males and 17% of females (41). Of those with arthritis, 14% had 
rheumatoid arthritis and 51% had osteoarthritis. The proportion of people with 
arthritis increased with age from less than 1% of people aged less than 25 
years to 48% of people aged 65 years and over. 
 
Overall, 3% of persons had osteoporosis: 1% of males and 5% of females. Like 
arthritis, the proportion of people with osteoporosis increased with age, from 
less than 1% of people aged less than 25 years to 16% of people aged 65 years 
and over. 
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Of those who reported currently having arthritis / osteoporosis, 34% discussed 
management of their arthritis / osteoporosis with a GP or specialist in the last 12 
months. It is this group, with more advanced disease, who may go on to pain 
management with opioid therapy (42). 
 
A study of the 15 years from 1992 until 2007 (the start of this study) shows 
there has been a continuous increase in total opioid prescribing in Australia. 
with a rapid increase in the use of oxycodone. This study included tramadol, a 
weak opioid, which is not a controlled opioid. Transdermal fentanyl and 
buprenorphine became available as PBS medicines in 2006 and only fentanyl is 
recorded (Figure 1.8). 
 
 
Figure 1.8 Number of PBS opioid prescriptions per annum 1992–2007 for 
fentanyl (2006), methadone, morphine, oxycodone and tramadol (2000) (43). 
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When looking at opioid prescriptions for CNCP patients in NW Tasmania, the 
situation differs. Data from the Pharmaceutical Services Branch (PSB) of the 
Department of Health for the first half of 2007, shows that morphine is the 
preferred OCR opioid medication for this group (Figure 1.9). 
Pr
es
cr
ip
tio
ns
bu
pr
en
or
ph
ine
 TD
fen
tan
yl 
TD
me
tha
do
ne
mo
rp
hin
e O
CR
ox
yc
od
on
e O
CR
mo
rp
hin
e I
R
ox
yc
od
on
e I
R
0
500
1000
1500
 
Figure 1.9 PBS opioid prescriptions dispensed in NW Tasmania during the 
first half of 2007 (excludes cancer / palliative care / nursing homes)  
(PSB internal data - Appendices 1.1, 1.2). 
Abbreviations: TD, transdermal: OCR, oral controlled release: IR, immediate 
release. 
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Table 1.1 Adverse effects of opioids (44). 
System Adverse effects 
cardiovascular bradycardia due to stimulation of the vagal nucleus in the 
medulla 
histamine release by morphine and morphine analogues, 
postural hypotension from peripheral vasodilation and 
baroreflex inhibition 
neurological dose-dependent mental clouding, delirium, sedation, nausea 
and vomiting, cough suppression, miosis, respiratory 
depression or apnoea, excitatory phenomena with myoclonus 
with high doses relative to renal function, 
dermatological sweating, flushing 
urticaria and pruritus due to histamine release 
gastrointestinal vomiting, anorexia, decreased gastric motility, increased 
antral tone, delayed gastric emptying, slowed digestion, 
prolonged large bowel transit time, increased anal sphincter 
tone, constipation  
neuroendocrine hypothalamic effects (including inhibition of gonadotrophin-
releasing hormone and corticotrophin-releasing factor) leading 
to decreased gonadotrophins, adrenocorticotrophic hormone, 
beta endorphin, testosterone and cortisol, and increased 
prolactin 
respiratory dose-related respiratory depression (which is more marked 
during sleep or with concomitant sedatives, hypnotics, and  
alcohol) 
bronchospasm due to histamine release 
urinary urinary retention and difficulty with micturition, increased 
external sphincter tone, decreased detrusor muscle tone, 
antidiuretic effect 
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1.4.1 Healthcare use literature 
Throughout 2007, the scientific literature, particularly the resources of the 
National Library of Medicine (PubMed), Thomson Reuters (Web of Science) 
and Google Scholar, were searched for the Medical Subject Heading (MeSH) 
term ‘Health Care Quality, Access, and Evaluation.’ This concept is concerned 
with all aspects of the quality, accessibility, and appraisal of health care and 
health care delivery. Modifiers were then added, to reduce the recovery of texts 
focused on cancer, palliative care, substance abuse, and acute pain (surgical), 
to produce the final search criteria: 
 
(((("Health Care Quality, Access, and Evaluation "[Mesh] AND "Analgesics, 
Opioid") NOT "Neoplasms"[Mesh]) NOT "Substance-Related Disorders"[Mesh]) 
NOT "Surgical Procedures, Operative"[Mesh]) NOT "Palliative Care"[Mesh]. 
 
There was a paucity of studies of healthcare use by patients with persistent 
pain, who required opioid medication. There were none that compared OCR 
and TD opioid use directly. 
 
A 2007 German study, entitled: ‘utilisation of medical resources of patients with 
pain undergoing an outpatient opioid therapy’, examined healthcare use, mainly 
from an economic perspective, using the German Federal Health Monitoring 
System (45). Fentanyl (reservoir) was the sole transdermal opioid studied. The 
authors conclude: ‘The number of consultations rose significantly after the first 
prescription of opioids. Patients with chronic pain, who are treated with long-
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lasting opioids for the first time, initially use considerably more healthcare 
resources. The type of opioid influences the amount of resource utilisation.’ 
 
The 2005 Danish study, entitled: ‘10-year follow-up of chronic non-malignant 
pain patients: opioid use, health related quality of life and health care utilization’, 
reported on 160 opioid and non-opioid using persistent pain patients whose 
healthcare use was compared pre and post Μultidisciplinary Pain Clinic (MPC) 
assessment (46). Their healthcare use peaked before MPC. Fentanyl 
(reservoir) was the sole transdermal opioid studied. The authors conclude that, 
‘health care utilization by chronic pain patients is very high and enormous 
medical and social resources are spent on these patients’. 
 
There were no current prospective studies that examined this issue, solely from 
the opioid use point of view, comparing differing routes of administration, in a 
rural / regional area. This was the driver for the present study. 
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1.5 North West Tasmania 
 
The North West of Tasmania, is defined by the Mersey-Lyell Statistical Division 
(SD) of the Australian Standard Geographical Classification (ASGC). This 
corresponds to the more familiar North West and West Coast of Tasmania 
Telephone Area Code (TAC) of 03 64xx xxxx. The region consists of nine Local 
Government Areas (LGAs) that are each identical to a Statistical Local Area 
(SLA), and have their associated Postal Areas (POAs) (Figure 1.10).   
 
Figure 1.10 NW Tasmania LGAs of Latrobe, Kentish, Devonport, Central 
Coast, Burnie, Waratah-Wynyard, Circular Head, and West Coast. 
 
This is a predominantly rural area with two centres of population, Devonport 
(east) and Burnie (central). The Tasmanian metropolitan areas of Launceston 
and Hobart are approximately two and four hours travel by road, respectively.  
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1.5.1 Regional and rural 
The revised Accessibility / Remoteness Index of Australia (ARIA+) defines five 
categories of Remoteness Area (RA) based on road distance between 
populated localities and service centres.(47) These distances are used to 
generate an RA score for any location in Australia. This is available for a variety 
of geographical units including LGAs and POAs. ARIA+ forms the basis for the 
Australian Bureau of Statistics "Remoteness Structure" component of the ASGC 
(Table 1.2). 
 
Table 1.2 Remoteness Area (RA) 
 
 
ARIA+ has been developed as an index (continuous variable with values 
between 0 and 15), based on a purely geographical calculation, in which 
remoteness is defined on the basis of road distance from any  point to the 
nearest town (service centre) in each of five population size classes. The 
population size of the service centre is used as a proxy for the availability of a 
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range of services and road distance is used as a proxy for the degree of 
remoteness from those services. 
 
The Mersey-Lyell Statistical Division is classified as ‘remote’ when compared to 
the Greater Hobart, Southern, and Northern regions (Figure 1.11) (Table 1.3). 
 
 
Figure 1.11  Tasmania SDs by RA (1=orange, 2=green, 3=blue). 
Abbreviations: SD, statistical division: RA, remoteness area. 
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Table 1.3 Tasmanian SD data (48). 
  
 
By RA classification, North West Tasmania is largely ‘Outer Regional’, with 
Circular Head and the West Coast being ‘Remote’, and King Island being ‘Very 
Remote’. Even the population centres of Burnie and Devonport are ‘Outer 
Regional’. The consequence of this is that for many of the region’s population, 
travel distance and time may have a significant impact on access to health care 
(Figure 1.12) (Table 1.4). 
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Figure 1.12  NW Tasmania LGAs by RA (2=green, 3=blue). 
Abbreviations: LGA, local government area: RA remoteness area. 
 
Table 1.4 NW Tasmania LGA data (49) 
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There is valid criticism of ARIA+ as an effective tool to guide health resource 
allocation, because ‘purely geographical classifications alone cannot capture all 
relevant aspects of rural health service provision within a single measure’ (50).  
The enhanced two-step floating catchment area (E2SFCA) method is an 
alternative tool for measuring access to healthcare resources within 
rural/regional areas. It assesses healthcare availability and population demand 
within travel time bands, and adjusts for the effect of distance (51). This has an 
Australian modification, as the Index for Rural Access, by incorporating a 
measure of health needs and mobility (52,53). However, throughout this study, 
ARIA+ has remained the Australian standard measure of Accessibility / 
Remoteness. 
29 
 
1.5.2 Socio-Economics 
To assess the socio-economic status of the region, the 2006 Index of Relative 
Socio-economic Disadvantage from the Australian Bureau of Statistics (ABS) is 
used. This is derived from Census variables related to disadvantage, such as 
low income, low educational attainment, unemployment, and dwellings without 
motor vehicles.  
These are scored, and given a decile place. Two thirds of NW Tasmania is at 
the third or lower decile, indicating that social mobility and access to health care 
may be difficult for many (Figure 1.13). 
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Figure 1.13 Index of relative socio-economic disadvantage (54) 
(the lower the score, the greater the disadvantage). 
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1.6 Conclusion 
 
The purpose of this study was to determine whether transdermal opioids reduce 
healthcare use in a rural pain population. To do this, the healthcare use of a NW 
Tasmanian pain population by their route of opioid administration will be 
compared. The choice between oral or transdermal administration of opioid 
medicines has only recently become available, hence the timeliness of this 
study. 
 
Healthcare use is measurable. The vehicle used here was a prospective 
observational longitudinal study, which is described in the following chapter. 
This is a robust tool to answer these research questions: 
 
For a chronic non-cancer pain population, in NW Tasmania, prescribed either 
oral or transdermal opioid analgesic medication... 
1 Is there a difference in healthcare utilisation? 
2 Is there a difference in the socio-economic costs involved? 
3 Is there a difference in the use of ‘breakthrough pain’ medication?
This chapter has been removed for
copyright or proprietary reasons. 
Henshaw, J. S., 2011. Do transdermal opioids 
reduce healthcare use in an Australian rural 
pain population? A comparison with oral 
opioids, Journal of opioid management , 7(2), 
135-144
This chapter has been removed for
copyright or proprietary reasons. 
Henshaw, J. S., Walker, J., Geraghty,D., 2012. 
Do transdermal opioids affect the personal 
socioeconomic costs of healthcare access in 
an Australian rural pain population? A 
comparison with oral opioids, Journal of 
opioid management 2012, 8(2), 126-132
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4 The effect on additional analgesic use
4.1 Abstract 
Objective: To determine the use of breakthrough immediate release opioids, 
and prescription only analgesics, with maintenance oral controlled release 
(OCR) and transdermal (TD) opioid treatment in a rural population with chronic 
non-cancer pain (CNCP). 
Design: A longitudinal study measuring Pharmaceutical Benefits Scheme 
(PBS) recorded analgesic dispensed prescriptions (scripts) by route of 
maintenance opioid administration over time (monthly for one year). Subjects 
were opioid treated CNCP patients from North West Tasmania. The outcome 
measures of mean monthly immediate release opioid, and prescription only 
analgesic, scripts by route of maintenance opioid administration were analysed 
using generalised estimating equations with robust standard errors. 
Results: The PBS details of 12191 dispensed scripts were obtained from 
140 subjects over 12 months. Mean monthly immediate release opioid scripts 
with maintenance OCR opioids were 0.21 (95%CI 0.10 to 0.32). With TD 
opioids this was non significantly lower (p=0.06) at 0.04 scripts (95%CI 0.00 to 
0.15). Mean monthly prescription only analgesic scripts with maintenance OCR 
opioids were 0.45 (95%CI= 0.28 to 0.62) and unchanged (p=0.94) for TD 
opioids at 0.46 (95%CI=0.21 to 0.72).  
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Conclusions:  A trend towards reduced breakthrough immediate release 
opioid use, by TD opioid treated, compared to OCR opioid treated, CNCP rural 
patients was observed. Prescription only analgesic use is similar with both 
routes of maintenance opioid treatment. Sedative (benzodiazepine), and 
antidepressant use is also similar. 
 
Modified content of this chapter has been accepted for publication by the 
Journal of Pain Research. 
 
Henshaw JS, Walker, J, Geraghty,D The effect of transdermal opioid use on 
‘breakthrough’ opioid and sedative prescribing for rural pain patients in North 
West Tasmania; a longitudinal study. 
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4.2 Introduction 
 
This study measured the use of breakthrough immediate release (IR) controlled 
opioids and prescription only analgesics in an opioid treated CNCP population 
in NW Tasmania.  
 
Prescription analgesics recorded were all non-controlled (Schedule 4 or 2) 
analgesics, including tramadol, codeine, paracetamol and NSAIDs, accessed 
through the Pharmaceutical Benefits Scheme (PBS) (91). Over the counter 
(OTC) medications were not recorded, as they are not PBS supplied 
medications and are freely available. 
 
The aim here was to determine if subjects prescribed TD opioids had similar 
breakthrough IR opioid, and prescription only (S4) analgesic use, to those 
prescribed OCR opioids. Any benefit in reduction of healthcare activity gained 
by using TD opioids, would be negated, particularly with IR opioid increase. 
 
The study additionally measured the co-prescribing of other neuroactive 
medicines, particularly sedatives (benzodiazepines) and antidepressants. 
Benzodiazepine use may increase opioid sedation, and their use between the 
TD and OCR opioid maintained subjects is compared. 
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4.3 Methods 
 
This longitudinal study measured change in the subjects’ PBS IR opioid, 
prescription only (S4) analgesic, sedative, and antidepressant, dispensed 
prescriptions over time (monthly for one year). Subjects were free to change 
their opioid medications (type, route, and dosage) throughout the study as 
prescribed by their treating doctor(s). The study was approved by the Human 
Research Ethics Committee (Tasmania) Network (approval number: H0009695) 
(Appendix 4.1). 
 
In Australia, for individual patient use, Schedule 8 (controlled) OCR and IR 
opioids are dispensed in packs of 20, and similarly with Schedule 4 prescription 
only analgesics. TD opioids are dispensed for two weeks duration. Sedative and 
antidepressant medications are usually supplied for four weeks (92). 
 
4.3.1 Subjects 
Study subjects were recruited from the previous observational study at its 
completion (2010). The inclusion criterion was consent to access their PBS data 
for the most recently available calendar year (2008) (Appendices 4.2 – 4.4). 
 
4.3.2 PBS data 
This data provided, by subject, the date of supply and the PBS Item Code of 
each prescription issued. Coding, using the WHO Anatomical Therapeutic 
Chemical (ATC) classification system, enabled identification of the subjects’ 
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controlled (opioid), non-controlled, and potential adjuvant analgesic 
prescriptions (93). The PBS item code was used to determine the route and 
preparation of the controlled opioid medications. Potential adjuvant analgesics 
were confined to neuroactive medications in the ATC N02C to N06A range 
(Table 4.1). All medicines were oral preparations apart from buprenorphine and 
fentanyl, which were transdermal. 
 
Table 4.1 ATC codes and ATC names. 
 ATC Code ATC Name 
Opioids (S8) N02AE01 buprenorphine (TD) 
 N02AB03 fentanyl (TD) 
 N02AA01 morphine (OCR / IR) 
 N02AC methadone 
 N02AA05 oxycodone (OCR/ IR) 
   
Analgesics (S4) N02AX02 tramadol 
 N02AA59 codeine / paracetamol 
   
Analgesics (S2) N02E01 paracetamol 
 M01A NSAIDs 
   
Sedatives (S4) N05BA / N05CD benzodiazepines 
   
Antidepressants (S4) N06AA TCA 
 N06AB SSRI 
 N06AX SNRI 
Abbreviation: ATC, anatomical therapeutic chemical 
 4.3.3 Statistical analysis 
Longitudinal (panel) data consists of a panel variable and a time variable. Here 
the panel variable was the subject and the time variable was the prescription 
month. Monthly prescriptions were uniquely identified by these two variables. 
80 
The number of monthly IR opioid, analgesic, sedative, and antidepressant 
prescriptions by opioid group, were then repeatedly compared over the study 
period. The variation in monthly prescriptions within individual subjects over 
time was less than between subjects. This correlation was recognised and dealt 
with statistically. 
The study outcome variables were mean monthly IR opioid (MIR), and 
analgesic (MA) prescriptions. The predictor variable was opioid group. The most 
frequent predictor characteristics were used to establish the reference mean 
MIR and MA (intercept). The change in mean MIR and MA (coefficient) which 
occurred if the predictor variable was present, the P value, and the 95% CI of 
this change were calculated.  
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4.4 Results 
 
Of the 198 subjects who provided data to the observational studies previously 
described, 148 consented to the release of their associated PBS data. Four of 
these received their medications through the Department of Veterans’ Affairs 
and four had ceased opioids. This provided 140 (71%) available datasets, with 
details of 12191 dispensed prescriptions for the study year (Appendices 4.5 -
4.8). 
 
There were 3133 controlled (S8) opioid prescriptions of which 896 (29%) were 
TD, and 324 (10%) were IR. For this study, methadone was included in the 
OCR group, as twice daily dosing is recommended for CNCP therapy (44) 
(Figure 4.1). 
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Figure 4.1 Controlled opioid scripts (n=3133). 
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Abbreviations: TD, transdermal: OCR, oral controlled release: IR, immediate 
release. 
 
This produced 1433 subject months of data classified by opioid group. There 
were subjects who combined TD and OCR opioids and some who only received 
IR opioids. Of the 406 TD months, 15 (4%) were combined with IR opioids. Of 
the 848 OCR months, 111 (13%) were so combined (Figure 4.2). 
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Figure 4.2 Opioid groups (n=1433). 
Abbreviations: TD, transdermal: OCR, oral controlled release: IR, immediate 
release. 
 
4.4.1 IR opioid use 
The GEE population averaged model of mean monthly IR opioid scripts (MIR) 
adjusted for clustering on subjects was calculated. With OCR opioids, the 
subject would have 0.21 (95%CI 0.10 to 0.32) IR opioid scripts dispensed per 
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month. With TD opioids this was non-significantly lower (p=0.06) at 0.04 (95%CI 
0.00 to 0.15) prescriptions (Table 4.2) (Figure 4.3). 
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Table 4.2 GEE population averaged model of mean monthly IR opioid 
scripts (MIR) adjusted for subject clustering (N=1379). 
Predictor variable Change in 
mean MIR 
P 95% CI n  % 
      
Opioid Group      
(Reference OCR)    848  61 
TD -0.16 0.06 -0.34 - 0.01 406 29 
TD OCR  0.02 0.89 -0.25 - 0.29 125 9 
       
Reference OCR      
Mean MIR  0.21  0.10 - 0.32   
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Figure 4.3 IR opioid, S4 analgesic, benzodiazepine, and antidepressant use 
(Mean, 95%CI, and P values) 
 
4.4.2 Prescription analgesic use 
There were 764 prescription only (S4) analgesic scripts dispensed, comprising 
the weak opioids tramadol and codeine, and the popular combination of codeine 
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with paracetamol. Additionally there were 907 scripts dispensed of the S2 
analgesics comprising anti-inflammatory preparations and paracetamol. The 
extended release (ER) preparation of paracetamol accounted for 41% of 
paracetamol prescriptions (Figure 4.4). 
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Figure 4.4 Analgesic scripts (n=1671). 
The GEE population averaged model of mean monthly S4 analgesic scripts 
(MA) adjusted for clustering on subjects was calculated. Mean MA with OCR 
opioids was 0.45 scripts (95%CI= 0.28 – 0.62) and unchanged (p=0.94) for TD 
opioids at 0.46 (95%CI=0.21 – 0.72) (Table 4.3) (Figure 4.3). 
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Table 4.3 GEE population averaged model of mean monthly analgesic 
scripts (MA) adjusted for subject clustering (N=1433). 
Predictor 
variable 
Change in 
mean MA 
P 95% CI n % 
      
Opioid Group      
(Reference OCR)    737 51 
TD .01 0.94 -0.30 -  0.32 391 27 
TD IR .51 0.22 -0.31 -  1.33 15 1 
OCR IR .01 0.88 -0.12 -  0.14 111 8 
TD OCR .16 0.29 -0.13 - 0.45 98 7 
TD OCR IR -.02 0.92 -0.46 - 0.42 27 2 
IR -.20 0.31 -0.56 - 0.18 54 4 
Reference OCR      
Mean MA .45  0.28 - 0.62   
 
4.4.3 Sedative and antidepressant use 
There were 796 benzodiazepine and 942 antidepressant prescriptions (Figure 
4.5). Antidepressants were represented as tricyclics (TCA), and selective 
noradrenaline (SNRI) and serotonin (SSRI) reuptake inhibitors. Both TCAs and 
SNRIs have use in the treatment of neuropathic pain and may have additive 
analgesic properties when used with opioids (12). 
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Figure 4.5 Benzodiazepine and antidepressant scripts (n=1738). 
Abbreviations: TCA, tricyclics: SNRI, selective noradrenaline reuptake 
inhibitors: SSRI, serotonin reuptake inhibitors. 
The GEE population averaged model of mean monthly benzodiazepine scripts 
and antidepressant scripts, adjusted for clustering on subjects was calculated. 
Mean monthly benzodiazepine scripts with OCR opioids were 0.47 (95%CI, 
0.32 to 0.62) and unchanged (p=0.84) for TD opioids at 0.45 (95%CI, 0.28 to 
0.62). Mean monthly antidepressant scripts with OCR opioids were 0.58 
(95%CI, 045 to 0.72) and unchanged (p=0.95) for TD opioids at 0.59 (95%CI, 
0.44 to 0.73) (Figure 4.3). 
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4.5 Discussion 
 
This longitudinal study compared breakthrough IR opioid and prescription only 
analgesic use by opioid treated CNCP rural patients. We have shown that 
requirements for breakthrough IR opioids may decrease with TD opioid 
preparations. Although this result is not statistically significant (P=0.06), the 
95% CI is largely negative. The rationale for use, and the provision of 
breakthrough opioid analgesia for CNCP patients is complex, both for patients 
and their prescribers (94).  
 
The present study shows that use of prescription only analgesic medications by 
this group were similar for both TD and OCR opioids. Likewise, sedative 
(benzodiazepine) and antidepressant use were similar 
 
This longitudinal study had inherent strengths and weaknesses. Being able to 
follow these categories of medication use by opioid treated CNCP subjects over 
twelve months with objective data recording through the PBS, was the major 
strength. Selection (recruitment) bias was the main potential weakness. 
Seventy five percent of the original study subjects were recruited for this 
subsequent study, with data from over twelve thousand prescriptions recorded. 
 
We have shown previously in opioid treated rural patients that the use of TD 
opioid preparations, with their prolonged analgesic effect, significantly reduce 
GP contacts and may reduce total healthcare activity. We have also shown that 
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the personal time and expense involved in accessing this healthcare is 
equivalent. The prescribing of TD opioids may particularly benefit this group of 
pain patients in rural areas where there is a relative shortage of doctors (87). 
The present study reinforces this conclusion by demonstrating a trend towards 
reduced breakthrough IR opioid use with no additional prescription only 
analgesic, sedative, or antidepressant use by these subjects. 
Prescribed analgesic use by opioid treated CNCP patients was a mix of weak 
opioids (tramadol and codeine) and non opioids (paracetamol and NSAIDs). 
There was frequent use of combination codeine/paracetamol medicines, which 
here accounted for one third of all prescribed analgesics. In Australia, there are 
currently no approved oxycodone/paracetamol preparations. These fixed 
combination medicines can make optimal paracetamol dosing complex for 
patients, and are incompatible with the extended release preparation. 
OTC analgesic use was not recorded, and is a potential confounder. These 
medications, primarily aspirin, paracetamol, and the NSAID ibuprofen, are 
available at all supermarkets and corner stores. NW Tasmania is an area of low 
socio-economic index, and patients may seek to obtain most analgesics as 
subsidised PBS medications through their GPs (82). 
There were three areas of pharmacotherapy potential concern. Firstly, the 
frequent use of sedative (benzodiazepines) medicines, which compound the 
sedation from the patients’ primary opioids (95). Secondly, 20% of prescribed 
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analgesics were tramadol, despite the frequent use of antidepressants, raising 
the risk of serotonin toxicity (44). Finally, there was the risk of paracetamol 
toxicity by patients combining OTC paracetamol with prescribed fixed 
combination codeine/paracetamol (96). 
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4.6 Conclusions 
This study from North West Tasmania showed that CNCP subjects maintained 
with TD opioids trend towards less breakthrough opioid medication. The use of 
prescription only analgesics, sedatives and antidepressants was equivalent to 
those maintained with OCR opioids. This may strengthen the case for more 
widespread use TD opioids in rural areas where healthcare access is often 
difficult. The continuing development of these systems is to be welcomed. 
In the final chapter, the effect transdermal opioids have had on the areas of pain 
relief, drug diversion, and pharmaco-economics, are discussed. Some future 
developments for their use in North West Tasmania are outlined. 
92 
5 The benefits of transdermal opioids 
5.1 Introduction 
There is nothing new under the sun. Transdermal opioid patches for pain were 
used in Ancient Greece for sporting injuries (97). The Greek physician Galen (c. 
129–200 BCE) makes particular reference to ‘Olympic Victor’s Dark Ointment’ 
(OVDO). He states that OVDO can be useful for treating extreme pain and 
swellings, forming one of the best eye salves (97). It was an opium-based 
treatment which forms a ‘patch’ when applied externally as an ointment, but still 
retains its elastic properties. When recreated using morphine as the opioid, 
OVDO ‘showed a transdermal transfer of morphine over time comparable to 
25% of the most efficient modern transdermal opioid patches’ (98). 
This study has demonstrated three possible benefits for rural/regional patients 
prescribed transdermal opioids for non-cancer pain (CNCP). First, there is a 
potential for less personal healthcare activity, particularly GP visits. Second, 
there is no increased socio-economic cost to bear. Third, there is potential for 
less need of ‘breakthrough’ opioid analgesia. Recent work has demonstrated a 
fourth benefit, the potential for increased compliance (99,100). 
Opioid therapy for CNCP remains controversial due to concerns regarding long-
term effectiveness and safety. The findings of a 2010 Cochrane Collaboration 
systematic review of 26 studies involving 4893 subjects ‘suggest that proper 
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management of opioids in well-selected patients can lead to long-term pain 
relief for some patients’ (101). The review reported that both OCR and TD 
opioids were effective in pain relief, but TD opioids were less likely to be 
discontinued due to adverse effects or poor analgesia (Figure 5.1).  They are, 
potentially, a more attractive option for rural patients and prescribers.  
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Figure 5.1 Reasons for ceasing opioid treatment for CNCP (mean and 
95%CI) (101). 
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5.2 Pain relief 
 
We know that TD opioids are as effective as OCR opioids in the treatment of 
persistent pain. What are the barriers to their more widespread use?  Prescriber 
familiarity and patient acceptance are probably the main issues. 
 
Doctors are very familiar with morphine and oxycodone. They are the main 
pillars of acute pain management in hospitals and in the community. Morphine 
is used parenterally, and oxycodone is used orally. Their dosing, administration, 
and adverse effects are well known. Because of this, their use as OCR 
medications is relatively straightforward. Additionally, these preparations have 
been available for more than twenty years with an extensive range of dosages 
available (26,28,30). 
 
Currently available TD opioids are either buprenorphine or fentanyl. 
Buprenorphine is well known to addiction medicine doctors for its use in the 
treatment of opioid dependence. Fentanyl is used frequently for short acting 
analgesia in anaesthesia and intensive care. However, outside of these circles, 
their use was very limited. Hence, until the availability of their TD preparations 
in 2005/6, most doctors were unfamiliar with the clinical use of these opioids 
(43). The dosage ranges available in Australia. are limited, with buprenorphine 
being available at lower, and fentanyl at higher, morphine equivalence (36,39). 
If analgesic requirements change markedly, the opioid has to be changed as 
well. This can be a complex task. 
95 
 
 
Patients realize that opioid medications, as with all medications, may have 
adverse effects. Pain relief from TD opioids is equivalent to that from oral 
opioids and adverse effects are potentially less. There is one issue relevant to 
all TD medications, but especially prominent with the TD buprenorphine 
preparation NorspanTM, that of skin irritation (102). All skin occlusive patches 
may produce skin irritation. If this is not a sensitivity reaction to the patch 
components, then it is the area of cover and the duration of administration, that 
drives this irritation. Even with site rotation, this may be a sufficient adverse 
effect to cause loss of compliance. Norspan preparations are large and are 
applied for seven days (Appendix 5.1). The TD fentanyl preparations 
DurogesicTM are small, and are applied for three days. 
 
These difficulties are readily surmountable in two ways. Firstly, prescriber 
therapeutic medical education is currently being provided by the National 
Prescriber Service (NPS). This provides an evidence-based guide to the 
therapeutic management of opioid therapy for CNCP patients. Prescribers may 
have confidence that their opioid prescribing practice is effective and current. 
Secondly, pharmaceutical companies are developing an increased range of TD 
opioid products. Higher dose ranges of TD buprenorphine with three day 
application are becoming available, and lower dose ranges of TD fentanyl are 
being developed (103). In the near future, prescriber familiarity and patient 
acceptance of TD opioid preparations should match that of the OCR opioid 
preparations. 
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With these developments, it may be possible to offer the benefits of TD opioid 
administration to patients with neoplastic disease. Due to the fluctuating nature 
of neoplastic pain and the limited range of TD opioid dosages, these patients 
have been managed with background OCR opioids and ‘breakthrough’ 
immediate release (IR) opioids. Neoplastic disease is more prevalent in the 
community due to increased survival and the aging population. Development of 
effective pain relief for these patients would be expanded, by the addition of TD 
opioid therapy to the mix. 
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5.3 Diversion 
 
All opioid analgesics approved by the TGA and available to patients via the PBS 
are Schedule 8 medications. They incur an additional layer of regulatory control 
above Schedule 4 prescription only medications. This is primarily to prevent 
diversion to the community for non-therapeutic purposes. 
 
OCR opioids are readily diverted. The Tasmanian Drug Trends (2011) report of 
the National Drug and Alcohol Research Centre (NDARC) found that for 
injecting drug users (IDUs), heroin was difficult to access (104). MS Contin 
remained the predominant (morphine) preparation, and OxyContin tablets were 
the predominant (oxycodone) formulation’ that were diverted for non-therapeutic 
purposes 
 
TD matrix opioid preparations are not mentioned by the IDUs included in this 
study. They may be diverted and the opioid may be injected, but with matrix 
preparations, this is a non-trivial task. The New Zealand Drug Intelligence 
Bureau concluded: ‘the buprenorphine transdermal patch, is not considered to 
be of significant potential for diversion or misuse for illicit purposes, whilst the 
NDARC found: ‘diverted fentanyl does not yet appear to pose a major threat to 
IDUs in Australia’ (105,106). The 2012 Tasmanian Police Corporate 
Performance Report indicates a substantial increase in seized oral opioids and 
benzodiazepines in NW Tasmania, with evidence that ‘some individuals are 
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legitimately obtaining prescription drugs and then on-selling them or trading 
prescription drugs for other drugs or property’ (107) (Figure 5.2). 
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Figure 5.2 Seized prescription oral opioids and benzodiazepines in NW 
Tasmania (2010 and 2011). 
 
If the risk of opioid diversion is a consideration in prescribing for CNCP patients 
then, at present, TD opioids are the safer option. If this leads to a reduction in 
the prevalence of opioid diversion in NW Tasmania, there are considerable 
economic benefits, both from a reduction in self-harm, and from drug 
enforcement costs. 
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5.4 Pharmaco-economics 
 
The term ‘pharmaco-economics’ refers to the comparative study of the value of 
one pharmaceutical drug therapy to another. It is a part of health economics. In 
this study, we were concerned with the comparison of OCR versus TD opioid 
therapy for CNCP in the context of rural and regional North West Tasmania. 
 
We have shown that TD opioids potentially reduce overall healthcare use and 
do reduce GP contact. We know that there is no patient socio-economic burden 
in achieving this. The use of ‘breakthrough’ IR opioids is potentially reduced, 
and there is no concomitant increase in prescription analgesia, sedative, or 
antidepressant use. Additionally, patients are more compliant with TD opioid 
dosing, and there is currently no evidence that in Tasmania, there is diversion to 
IDUs.  
 
Although this was not the prime focus, our results suggest that from a holistic 
pharmacoeconomic view, TD opioids are superior to OCR opioids in the context 
of this study. NW Tasmania is not unlike other rural and regional areas of 
Australia, and these results may well be applicable more widely. 
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5.5 Future research 
 
This study has not examined the therapeutic implications of using transdermal 
versus oral routes of administration for these opioid analgesics in this 
population. To do so requires knowledge of the effectiveness of these 
medicines in alleviating daily pain, and in increasing the activities of daily living. 
In my view, this may require the multi centre cooperation of rural pain units to 
provide the necessary research resources. 
 
There remain many gaps in our knowledge of the effective use of opioid 
analgesics in maintenance of CNCP rural patients. These are not static targets, 
as both the populations and the opioid medications develop. 
 
Aging is the primary change in this population. The ‘Baby Boomer’ cohort is 
beginning to feel its age. They are developing the same painful degenerative 
musculoskeletal changes as their parents, perhaps without the same stoic 
philosophy. This will place a particular burden on future healthcare provision of 
effective pain relief. 
 
Opioid medications are changing. The lower dose ranges of both OCR and TD 
opioids have been expanding, providing more flexibility in managing the elderly 
and infirm. The addition of low dose opioid antagonists to OCR preparations is 
increasingly being used to mitigate against medication diversion (108) 
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The aim, as always, is to provide the most effective outcomes for rural pain 
populations, where resources will always be limited. This study is but one-step 
in that direction.
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5.6 Conclusion 
 
‘Peter’ is a retired farmer who lives with his wife outside of Sheffield, the nearest 
town to Cradle Mountain National Park. He had been physically active for all his 
working life, but was eventually forced off his land by significant painful spinal 
degeneration, which made tractor driving unbearable. He has had diabetes and 
hypertension for many years, which precluded regular anti-inflammatory use. By 
2005, his GP decided that Peter might benefit from low dose opioid medication 
to manage his pain, and improve his mobility. A trial of oral MS Contin helped, 
but, in spite of instructions, he would only take them if his pain was unbearable. 
However stubborn Peter may have been, his GP was his match. In the winter of 
2006, she trialled him with the newly released buprenorphine weekly patch, 
which the practice nurse trained Peter’s wife to apply correctly. Peter still uses 
these patches, he is mobile around the house and garden, and his joy is his 
great grandchildren.  
 
In 2006, Peter’s GP knew that transdermal opioids were as effective as oral 
opioids of equivalent dosage. She did know what effect using these medicines 
would have on overall healthcare activity for her patients. This study has shed 
some light on this issue, by following the journey of 198 men and women like 
Peter.  
 
Between 2007 and 2010, these study subjects provided 1804 monthly diary 
pages of their out-of-home healthcare activity, detailing 10564 individual 
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healthcare contacts. From this data, a picture of the healthcare activity of opioid 
treated persistent pain patients throughout NW Tasmania emerged. 
 
This longitudinal study compared healthcare activity by patients using oral or 
transdermal opioids. There is a personal socioeconomic cost involved 
accessing healthcare, more so in rural areas. Pain patients may use additional 
analgesics with their opioids. These related issues were assessed, as any 
benefit from reduced healthcare activity would likely be lost if patient costs, or 
their need for additional analgesics, increased.  
 
GP contacts were reduced significantly, and there was a trend towards less 
total healthcare activity, by patients using transdermal opioids.  Their personal 
socioeconomic costs involved remained unchanged. Additional analgesic use 
was unchanged, but there was a trend towards reduced use of short acting 
opioids for ‘breakthrough’ pain. Whether some patients have individual 
characteristics that enhance their response to the ‘steady state’ delivery of 
opioid medication by the transdermal route is currently unknown. 
 
In NW Tasmania, transdermal opioids do seem to offer a benefit to patients 
compared to oral opioids. Reducing the frequency of GP visits is a good 
outcome in this rural area of limited health resources. 
 
Transdermal opioids are relatively simple and safe to use, both for prescribers 
and patients. As the population here ages, there will be an increased 
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requirement for safe and effective pain relief for both degenerative and 
malignant pain. With the development of these preparations, transdermal matrix 
opioids may open the door to the further relief of suffering and the living of 
fulfilled lives. 
105 
 
References 
 
1. Pharmaceutical Benefits Advisory Committee. Buprenorphine, transdermal patch, 5 mg, 
10 mg and 20 mg, Norspan®, . Department of Health and Ageing; 2005 [cited 01 January 2010]; 
Available from: http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-
buprenorphine. 
2. Reginster JY. The prevalence and burden of arthritis. Rheumatology 2002;41(90001):3-6. 
3. Dickson DJ. Opioids for non-operable osteoarthritis and soft-tissue rheumatism. Arthritis 
Research & Therapy 2005(7):193-4. 
4. McQuay H J. Opioid use in chronic pain. Bandolier [serial online] [cited 01 December 
2009]. Available from: http://www.medicine.ox.ac.uk/bandolier/booth/painpag/wisdom/S31.html. 
5. McNicol E. Opioid Side Effects. Pain: clinical Updates 2007;Volume XV, Issue 2. 
6. NPS RADAR. Buprenorphine transdermal patches (Norspan) for chronic severe pain. 
National Prescribing Service; 2005 [cited 01 January 2010]; Available from: 
http://www.npsradar.org.au/site.php?page=1&content=/npsradar/content/buprenorphine.html. 
7. Janssen-Cilag Pty Ltd. Fentanyl patches (Durogesic) for chronic pain. Correspondence 
from Janssen-Cilag Pty Ltd [serial online] 2006 [cited 01 December 2009]. Available from: 
http://www.npsradar.org.au/site.php?page=1&content=/npsradar/content/fentanyl.html. 
8. Pharmaceutical Benefits Advisory Committee. Fentanyl, transdermal patch, Durogesic® 
12/25/50/75/100. Department of Health and Ageing; 2006 [cited 01 January 2010]; Available from: 
http://www.health.gov.au/internet/main/publishing.nsf/Content/pbac-psd-fentanylpatch-mar06. 
9. Ballantyne JC, Mao JR. Opioid therapy for chronic pain. New England Journal of 
Medicine 2003;349(20):1943-53. 
10. McQuay H J. Moore R A. Opioid problems, and morphine metabolism and excretion. 
Bandolier [serial online] [cited 01 December 2009]. Available from: 
http://www.medicine.ox.ac.uk/bandolier/booth/painpag/wisdom/c14.html#RTFToC3. 
11. DHHS. Protocol for Opioid Prescribing in Tasmania; 2008 [cited 31 Dec 2010]; Available 
from: 
http://www.dhhs.tas.gov.au/__data/assets/pdf_file/0004/77701/Protocol_for_prescribing_opioids_in
_Tasmania.pdf. 
12. Shipton EA, Tait B. Flagging the pain: preventing the burden of chronic pain by 
identifying and treating risk factors in acute pain. European Journal of Anaesthesiology 
2005;22(06):405-12. 
13. Merskey H, Bogduk N. Classification of chronic pain : descriptions of chronic pain 
syndromes and definitions of pain terms. Seattle: IASP Press; 1994. 
14. Descartes R. La description du corps humain; 1640. 
15. Melzack R, Wall PD. Pain mechanisms: a new theory. Science 1965;150(699):971-9. 
16. Loeser JD. Pain and suffering. Clin J Pain 2000;16(2 Suppl):S2-6. 
17. Clark D. From margins to centre: a review of the history of palliative care in cancer. 
Lancet Oncology 2007;8(5):430-8. 
18. Saunders CM. The care of the terminal stages of cancer. Ann R Coll Surg Engl 
1967;41(Suppl):162-9. 
19. Brescia FJ. A study of controlled-release oral morphine (MS Contin) in an advanced 
cancer hospital. J Pain Symptom Manage 1987;2(4):193-8. 
20. Schug S, Merry A, Acland R. Treatment principles for the use of opioids in pain of 
nonmalignant origin. Drugs 1991;42(2):228. 
21. Portenoy RK, Foley KM. Chronic use of opioid analgesics in non-malignant pain: report of 
38 cases. Pain 1986;25(2):171-86. 
22. Amabile CM, Bowman BJ. Overview of oral modified-release opioid products for the 
management of chronic pain. Ann Pharmacother 2006;40(7-8):1327-35. 
23. Shafer SL, Varvel JR. Pharmacokinetics, pharmacodynamics, and rational opioid 
selection. Anesthesiology 1991;74(1):53-63. 
24. Mather LE. The clinical effects of morphine pharmacology. Regional Anesthesia and Pain 
Medicine 1995;20(4):263-82. 
106 
 
25. Analgesic Expert G, Mashford ML, Writing Group for Therapeutic Guidelines: Analgesic. 
Therapeutic guidelines : analgesic. 5th ed. North Melbourne, Vic.: Therapeutic Guidelines Ltd.; 
2007. 
26. Mundipharma P/L. MS Contin Product Information; 2010 [cited 31 Dec 2010]; Available 
from: http://secure.healthlinks.net.au/content/mf/pi.cfm?product=mfpmscon. 
27. Mundipharma P/L. MS Mono Product Information; 2010 [cited 31 Dec 2010]; Available 
from: http://secure.healthlinks.net.au/content/mf/pi.cfm?product=mfpmsmon. 
28. GlaxoSmith Kline P/L. Kapanol Product Information; 2010 [cited 31 Dec 2010]; Available 
from: 
http://www.gsk.com.au/resources.ashx/prescriptionmedicinesproductschilddataproinfo/1163/FileNa
me/00E57814FC409E85CA269ABD1BDF8C70/Kapanol_PI.pdf. 
29. Poyhia R, Seppala T, Olkkola KT, Kalso E. The pharmacokinetics and metabolism of 
oxycodone after intramuscular and oral administration to healthy subjects. Br J Clin Pharmacol 
1992;33(6):617-21. 
30. Mundipharma P/L. Oxycontin Product Information; 2010 [cited 31 Dec 2010]; Available 
from: http://secure.healthlinks.net.au/content/mf/pi.cfm?product=mfpoxyco. 
31. Fishman SM, Wilsey B, Mahajan G, Molina P. Methadone reincarnated: novel clinical 
applications with related concerns. Pain Med 2002;3(4):339-48. 
32. Caplehorn JR. Deaths in the first two weeks of maintenance treatment in NSW in 1994: 
identifying cases of iatrogenic methadone toxicity. Drug and Alcohol Review 1998;17(1):9-17. 
33. GlaxoSmith Kline P/L. Physeptone Product Information; 2010 [cited 31 Dec 2010]; 
Available from: 
http://www.gsk.com.au/resources.ashx/prescriptionmedicinesproductschilddataproinfo/356/FileNa
me/5A214ADFE87D800CFEE239FFBE310FF1/PI_Physeptone.pdf. 
34. Caplan R SM. Transdermal drug delivery and its application to pain control. Advances in 
Pain Research and Therapy 1990;14::233-40. 
35. Walsh SL, Preston KL, Stitzer ML, Cone EJ, Bigelow GE. Clinical pharmacology of 
buprenorphine: ceiling effects at high doses. Clinical Pharmacology & Therapeutics 
1994;55(5):569-80. 
36. Mundipharma P/L. Norspan Product Information. AusDI; 2010 [cited 31 Dec 2010]; 
Available from: http://secure.healthlinks.net.au/content/mf/pi.cfm?product=mfpnorsp. 
37. Margetts L, Sawyer R. Transdermal drug delivery: principles and opioid therapy. 
Continuing Education in Anaesthesia, Critical Care & Pain 2007;7(5):171-6. 
38. Mather L. Clinical pharmacokinetics of fentanyl and its newer derivatives. Clinical 
pharmacokinetics 1983;8(5):422. 
39. Janssen-Cilag P/L. Durogesic Product Information; 2010 [cited 31 Dec 2010]; Available 
from: http://www.janssen.com.au/files/Products/Durogesic_PI.pdf. 
40. Barrack RL, Paprosky W, Butler RA, Palafox A, Szuszczewicz E, Myers L. Patients' 
perception of pain after total hip arthroplasty. The Journal of Arthroplasty 2000;15(5):590-6. 
41. Australian Bureau of Statistics. 4364.0 - National Health Survey: Summary of Results, 
2007-2008 (Reissue) [cited 01 January 2010]; Available from: 
http://www.abs.gov.au/ausstats/abs@.nsf/Latestproducts/4364.0Main%20Features32007-
2008%20(Reissue)?opendocument&tabname=Summary&prodno=4364.0&issue=2007-
2008%20(Reissue)&num=&view=. 
42. Solomon DH, Avorn J, Wang PS, Vaillant G, Cabral D, Mogun H, et al. Prescription 
opioid use among older adults with arthritis or low back pain. Arthritis Rheum 2006;55(1):35-41. 
43. Leong M, Murnion B, Haber P. Examination of opioid prescribing in Australia from 1992 
to 2007. Intern Med J 2009;39(10):676-81. 
44. Therapeutic guidelines : analgesic. 5th ed. North Melbourne, Vic.: Therapeutic Guidelines 
Ltd.; 2007. 
45. Bruggenjurgen B, Burkowitz J, Willich SN. [Utilisation of medical resources of patients 
with pain undergoing an outpatient opioid therapy]. Gesundheitswesen 2007;69(6):353-8. 
46. Jensen MK, Thomsen AB, Hojsted J. 10-year follow-up of chronic non-malignant pain 
patients: opioid use, health related quality of life and health care utilization. Eur J Pain 
2006;10(5):423-33. 
47. Australian Standard Geographical Classification (ASGC), Jul. 2008 [cited 01 December 
2009]:1216.0. Available from: 
107 
 
http://www.abs.gov.au/AUSSTATS/ABS@.NSF/Latestproducts/9656E5415D2B0A07CA2574CF001
37F89?opendocument. 
48. GISCA. ARIA+ by Statistical Division. Adelaide: National Centre for Social Applications 
of GIS; 2006. 
49. GISCA. ARIA+ by Statistical Local Area: National Centre for Social Applications of GIS; 
2006. 
50. McGrail MR, Humphreys JS. Geographical classifications to guide rural health policy in 
Australia. Australia and New Zealand Health Policy 2009;6(1):28. 
51. Luo W, Qi Y. An enhanced two-step floating catchment area (E2SFCA) method for 
measuring spatial accessibility to primary care physicians. Health Place 2009;15(4):1100-7. 
52. McGrail MR, Humphreys JS. A new index of access to primary care services in rural 
areas. Aust N Z J Public Health 2009;33(5):418-23. 
53. McGrail MR, Humphreys JS. The index of rural access: an innovative integrated approach 
for measuring primary care access. BMC Health Serv Res 2009;9:124. 
54. SEIFA: Socio-Economic Indexes for Areas. Australian Bureau of Statistics; 2006; 
Available from: http://www.abs.gov.au/websitedbs/D3310114.nsf/home/Seifa_entry_page. 
55. Merck & Co. Merck Announces Voluntary Worldwide Withdrawal of VIOXX®; 2004; 
Available from: http://www.merck.com/newsroom/vioxx/pdf/vioxx_press_release_final.pdf. 
56. Graham D, Campen D, Hui R, Spence M, Cheetham C, Levy G, et al. Risk of acute 
myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective 
and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. The Lancet 
2005;365(9458):475-81. 
57. Moore RA, Derry S, McQuay HJ. Cyclo-oxygenase-2 selective inhibitors and nonsteroidal 
anti-inflammatory drugs: balancing gastrointestinal and cardiovascular risk. BMC Musculoskelet 
Disord 2007;8:73. 
58. Australian Bureau of Statistics. 3235.0 - Population by Age and Sex, Regions of Australia, 
2008 [cited 01 January 2010]; Available from: 
http://www.abs.gov.au/ausstats/abs@.nsf/Products/3235.0~2008~Main+Features~Tasmania?OpenD
ocument. 
59. Cradle Coast Authority. Cradle Coast Region, Tasmania; 2005 [cited 01 January 2010]; 
Available from: http://www.cradlecoast.com/pdf/cradlecoast/00375_Profile-Intro.pdf. 
60. Blyth F, M., March L, M., Brnabic A, J. M., Cousins M, J. Chronic pain and frequent use 
of health care. Pain 2004;111(1):51-8. 
61. Pharmaceutical Service Branch. Alcohol and Drug Dependency Act 1968. Department of 
Health and Human Services, Tasmania[cited 01 January 2010]; Available from: 
http://www.dhhs.tas.gov.au/psbtas/pharmaceutical_services. 
62. National Prescribing Service. MedicinesTalk: Private prescriptions. 15; Spring 2005 [cited 
01 January 2010]; Available from: 
http://www.nps.org.au/consumers/publications/medicines_talk/mt15/private_prescriptions2. 
63. Department of Health and Aged Care. Chief Medical Officer's Report 1999-2000 [cited 01 
Jnauary 2010]; Available from: 
http://www.health.gov.au/internet/main/publishing.nsf/Content/D2842B480285116BCA256F180056
8976/$File/cmo2000_11.pdf. 
64. Reeves MD, Ginifer CJ. Fatal intravenous misuse of transdermal fentanyl. The Medical 
Journal of Australia 2002;177(10):552-3. 
65. NPS RADAR. Fentanyl patches (Durogesic) for chronic pain. National Prescribing Service; 
2006 [cited 01 January 2010]; Available from: 
http://www.nps.org.au/health_professionals/publications/nps_radar/2006/august_2006/fentanyl_pat
ches. 
66. Hunter Integrated Pain Service. Opioid Use in Persistent Pain; 2011 [cited 31 Dec 2011]; 
Available from: 
http://www.hnehealth.nsw.gov.au/__data/assets/pdf_file/0007/76039/opioid_use_Nov_2010_2.pdf. 
67. Mundipharma P/L. Oxycontin Product Information. AusDI; 2009 [cited 01 January 2010]; 
Available from: http://proxy15.use.hcn.com.au/html/p?id=p00620. 
68. Sittl R, Likar R, Nautrup BP. Equipotent doses of transdermal fentanyl and transdermal 
buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. 
Clin Ther 2005;27(2):225-37. 
108 
 
69. Weschules DJ, Bain KT. A systematic review of opioid conversion ratios used with 
methadone for the treatment of pain. Pain Med 2008;9(5):595-612. 
70. Everitt B. Medical statistics from A to Z : a guide for clinicians and medical students. 2nd 
ed. Cambridge, UK ; New York, NY: Cambridge University Press; 2006. 
71. Fitzmaurice GM, Laird NM, Rotnitzky AG. Regression models for discrete longitudinal 
responses. Statistical Science 1993;8(3):284-99. 
72. Liang KY, Zeger SL. Longitudinal data analysis using generalized linear models. 
Biometrika 1986;73(1):13. 
73. Stata/IC 11. StataCorp LP, College Station, Texas 77845. 
74. Dupont WD PW. PS power and sample size program available for free on the Internet. 
Controlled Clinical Trials 1997(18):274. 
75. Tu XM, Kowalski J, Zhang J, Lynch KG, Crits-Christoph P. Power analyses for 
longitudinal trials and other clustered designs. Stat Med 2004;23(18):2799-815. 
76. Twisk JWR. Applied longitudinal data analysis for epidemiology : a practical guide. 
Cambridge, UK ; New York: Cambridge University Press; 2003. 
77. Norspan Product Information. AusDI; 2009 [cited 01 January 2010]; Available from: 
http://proxy15.use.hcn.com.au/html/p?id=p01828. 
78. Stenhouse E, Wright DE, Hattersley AT, Millward BA. Weight differences in Plymouth 
toddlers compared to the British Growth Reference Population. Arch Dis Child 2004;89(9):843-4. 
79. Ekholm O, Gronbaek M, Peuckmann V, Sjogren P. Alcohol and smoking behavior in 
chronic pain patients: the role of opioids. Eur J Pain 2009;13(6):606-12. 
80. Henshaw JS. Do transdermal opioids reduce healthcare use in an Australian rural pain 
population? A comparison with oral opioids. J Opioid Manag 2011;7(2):135-44. 
81. AIHW. Australian health expenditure by remoteness: a comparison of remote, regional 
and city health expenditure. Australian Institute of Health and Welfare; 2011 [cited 01 03 2011]; 
Available from: www.aihw.gov.au/publication-detail/?id=6442475421. 
82. Australian Bureau of Statistics. Socio-Economic Indexes for Areas (SEIFA), Australia; 
2006 [cited 01 January 2010]; Available from: 
http://www.abs.gov.au/AUSSTATS/abs@.nsf/Lookup/2033.0.55.001Main+Features12006?OpenDoc
ument. 
83. Guidelines for dispensing of medicines, Section 11, Pharmacists’ Workloads. Pharmacy 
Board of Australia; 2010 [cited 2010 1st July]; Available from: 
http://www.pharmacyboard.gov.au/Codes-Guidelines.aspx. 
84. Medicare Benefits Schedule. Department of Health and Aging; 2008 [cited 31 October 
2010]; Available from: 
http://www.health.gov.au/internet/mbsonline/publishing.nsf/Content/MBSOnline-2008. 
85. Bulk Billing FAQ. Medicare Australia; 2010 [cited 2010 July 1st]; Available from: 
http://www.medicareaustralia.gov.au/provider/medicare/bulk-billing.jsp. 
86. Overview of the PBS Safety Net. Medicare Australia; 2010 [cited 2010 July 1st]; Available 
from: http://www.medicareaustralia.gov.au/public/services/scripts/pbs.jsp. 
87. Report on the Audit of Health Workforce in Rural and Regional Australia. Australian 
Government Department of Health and Ageing; 2008 [cited 01 January 2010]; Available from: 
http://www.health.gov.au/internet/main/publishing.nsf/Content/work-res-ruraud. 
88. 6306.0 - Employee Earnings and Hours. Australian Bureau of Statistics; 2009 [cited 30 
October 2010]; Available from: http://www.abs.gov.au/ausstats/abs@.nsf/mf/6306.0/. 
89. Centrelink. News for Seniors 78. 2009 [cited 31 October 2010]. Available from: 
http://www.centrelink.gov.au/internet/internet.nsf/filestores/rt010_0907/$file/rt010_0907en.pdf. 
90. WHO. Memberstates and Medicines Price Information; 2010 [cited 31 Dec 2011]; 
Available from: 
http://www.who.int/medicines/areas/access/ecofin_who_memberstates/en/index.html. 
91. Poisons List Order 2001. Tasmanian Government; 2001 [cited 31 Dec 2011]; Available 
from: http://www.thelaw.tas.gov.au/tocview/index.w3p. 
92. Department of Health and Aging. PBS Schedule; 2008 [cited 31 Dec 2011]; Available from: 
http://pbs.gov.au/browse/medicine-listing. 
93. ATC/DDD Index 2012. WHO Collaborating Centre for Drug Statistics Methodology; 
Available from: http://www.whocc.no/atc_ddd_index/. 
94. Manchikanti L, Singh V, Caraway DL, Benyamin RM. Breakthrough pain in chronic non-
cancer pain: fact, fiction, or abuse. Pain Physician 2011;14(2):E103-17. 
109 
 
95. Manchikanti L, Manchikanti KN, Pampati V, Cash K. Prevalence of side effects of 
prolonged low or moderate dose opioid therapy with concomitant benzodiazepine and/or 
antidepressant therapy in chronic non-cancer pain. Pain Physician 2009;12(1):259-67. 
96. Ayonrinde O, Phelps G, Hurley J, Ayonrinde O. Paracetamol overdose and hepatotoxicity 
at a regional Australian hospital: a 4‐year experience. Internal Medicine Journal 2005;35(11):655-
60. 
97. Bartels EM, Swaddling J, Harrison AP. An ancient Greek pain remedy for athletes. Pain 
Practice 2006;6(3):212-8. 
98. Harrison AP, Hansen SH, Bartels EM. Transdermal Opioid Patches for Pain Treatment in 
Ancient Greece. Pain Practice 2012. 
99. Collado F, Torres LM. Association of transdermal fentanyl and oral transmucosal fentanyl 
citrate in the treatment of opioid naive patients with severe chronic noncancer pain. J Opioid 
Manag 2008;4(2):111-5. 
100. James IG, O'Brien CM, McDonald CJ. A randomized, double-blind, double-dummy 
comparison of the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans 
seven-day patches) with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis 
pain. J Pain Symptom Manage 2010;40(2):266-78. 
101. Noble M, Treadwell JR, Tregear SJ, Coates VH, Wiffen PJ, Akafomo C, et al. Long-term 
opioid management for chronic noncancer pain. Cochrane Database Syst Rev 2010(1):CD006605. 
102. Hans G, Robert D. Transdermal buprenorphine - a critical appraisal of its role in pain 
management. J Pain Res 2009;2:117-34. 
103. Napp Pharmaceuticals Limited. Transtec product information; 2010 [cited 31 Dec 2011]; 
Available from: 
http://www.medicines.org.uk/EMC/medicine/8864/SPC/Transtec+35%2c+52.5+and+70+microgram
s++transdermal+patch/. 
104. National Drug and Alcohol Research Centre (NDARC). Tasmanian Drug Trends 2011: 
Findings from the Illicit Drug Reporting System (IDRS). ; 2011 [cited 31 Dec 2011]; Available 
from: http://ndarc.med.unsw.edu.au/resource/tasmanian-drug-trends-2011-findings-illicit-drug-
reporting-system-idrs. 
105. National Drug Intelligence Bureau. Buprenorphine in New Zealand; 2007 [cited 31 Dec 
2010]; Available from: http://www.ndp.govt.nz/moh.nsf/pagescm/7457/$File/buprenorphine.pdf. 
106. Gibson A, Larance B, Roxburgh A, Degenhardt L, Black E. The extent of diversion of 
fentanyl for non-medical puposes in Australia: What do we know? Randwick, NSW: National Drug 
& Alcohol Research Centre; 2007. 
107. Tasmanian Police. May 2012 Corporate Performance Report [cited 31 May 2012]; 
Available from: http://www.police.tas.gov.au/right-to-information/our-
disclosures/routine/corporate-performance-report/. 
108. Chindalore VL, Craven RA, Yu KP, Butera PG, Burns LH, Friedmann N. Adding 
ultralow-dose naltrexone to oxycodone enhances and prolongs analgesia: a randomized, controlled 
trial of Oxytrex. J Pain 2005;6(6):392-9. 
 
